Takeda Loses Appellate Bid to Bar Copycats of Colcrys Gout Drug

Takeda Pharmaceuticals U.S.A. failed to convince the Federal Circuit that Mylan Pharmaceuticals Inc. and Alkem Laboratories Ltd. should be barred from selling generic versions of its gout drug Colcrys.

The U.S. District Court for the District of Delaware denied Takeda’s motions for preliminary injunctions in separate cases against the generic makers. Takeda argued its licensing agreements with Mylan and Alkem don’t allow them to sell generics yet.

A divided U.S. Court of Appeals for the Federal Circuit affirmed denial of the injunctions in two opinions Friday.

Takeda’s reading of the agreements “leads to the absurd result that Takeda could prevent ...